{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:51:00Z","timestamp":1789008660250,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T04:15:09Z","timestamp":1499919309000},"page":"797-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-2333","authenticated-orcid":false,"given":"Moaath","family":"Mustafa Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Nomani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Rouphail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Pohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.07.002_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdllow","year":"2008"},{"key":"10.1016\/j.clml.2017.07.002_bib2","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.002_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3324\/haematol.12754","article-title":"Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas","volume":"93","author":"Piccaluga","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.07.002_bib4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.07.002_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.07.002_bib6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/annonc\/mdq574","article-title":"Follicular non-Hodgkin lymphoma Grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy","volume":"22","author":"Shustik","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.07.002_bib7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","article-title":"Clinical, pathological and genetic features of follicular lymphoma Grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL","volume":"27","author":"Koch","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.07.002_bib8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with Grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.07.002_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.5858\/2004-128-863-ACEOFL","article-title":"A\u00a0clinicopathologic evaluation of follicular lymphoma Grade 3A versus Grade 3B reveals no survival differences","volume":"128","author":"Hsi","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2017.07.002_bib10","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.clml.2017.07.002_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.002_bib12","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.humpath.2013.06.013","article-title":"Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy","volume":"44","author":"Maeshima","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2017.07.002_bib13","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.002_bib14","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.002_bib15","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.30137","article-title":"Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer Research Group (E1496)","volume":"122","author":"Barta","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.07.002_bib16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.07.002_bib17","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017307450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017307450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:00Z","timestamp":1761870720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017307450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017307450"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}